Works matching IS 08909091 AND DT 2022 AND VI 36 AND IP 5
Results: 8
Emerging Therapies for Relapsed/ Refractory Multiple Myeloma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 330
- By:
- Publication type:
- Article
Reducing Busy Work for the Busy Doctor.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 323
- Publication type:
- Article
EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Dostarlimab.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 321
- By:
- Publication type:
- Article
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 316
- By:
- Publication type:
- Article
Current Treatment of Peripheral T-cell Lymphoma.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 293
- By:
- Publication type:
- Article
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 276
- By:
- Publication type:
- Article
Increasing Knowledge About Integrative Oncology May Serve to Reduce Cancer Burden.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 268
- By:
- Publication type:
- Article
CRISPR Patent Battle: Beautiful Science, Poor Public Policy.
- Published in:
- Oncology (08909091), 2022, v. 36, n. 5, p. 263
- By:
- Publication type:
- Article